Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers
Khine S. Shan,Shivani Dalal,Nyein Nyein Thaw Dar,Omani McLish,Matthew Salzberg,Brian A. Pico
DOI: https://doi.org/10.3390/ijms25020849
IF: 5.6
2024-01-11
International Journal of Molecular Sciences
Abstract:Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases that are involved in the regulation of cell proliferation, survival, and development. FGFR alterations including amplifications, fusions, rearrangements, and mutations can result in the downstream activation of tyrosine kinases, leading to tumor development. Targeting these FGFR alterations has shown to be effective in treating cholangiocarcinoma, urothelial carcinoma, and myeloid/lymphoid neoplasms, and there are currently four FGFR inhibitors approved by the Food and Drug Administration (FDA). There have been developments in multiple agents targeting the FGFR pathway, including selective FGFR inhibitors, ligand traps, monoclonal antibodies, and antibody–drug conjugates. However, most of these agents have variable and low responses, with some intolerable toxicities and acquired resistances. This review will summarize previous clinical experiences and current developments in agents targeting the FGFR pathway, and will also discuss future directions for FGFR-targeting agents.
biochemistry & molecular biology,chemistry, multidisciplinary